UK markets closed

ACADIA Pharmaceuticals Inc. (ACAD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
23.56+0.16 (+0.68%)
At close: 04:00PM EDT
23.56 0.00 (0.00%)
After hours: 05:26PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close23.40
Bid22.90 x 2200
Ask24.00 x 1300
Day's range22.99 - 23.74
52-week range13.73 - 33.99
Avg. volume1,623,527
Market cap3.857B
Beta (5Y monthly)0.57
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Simply Wall St.

    When Can We Expect A Profit From ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?

    ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) is possibly approaching a major achievement in its business, so we would...

  • Motley Fool

    2 Supercharged Growth Stocks Billionaires Can't Stop Buying

    If you are looking for some high-octane growth stocks to add to your portfolio, you might want to follow in the footsteps of some of the most successful investors in the biotech sector. Baker Bros. Advisors, a hedge fund founded by billionaire brothers Julian and Felix Baker, has a stellar track record of picking winners in the healthcare space. Two of the fund's top holdings are Acadia Pharmaceuticals (NASDAQ: ACAD) and Roivant Sciences (NASDAQ: ROIV), both of which have delivered impressive returns in the past year.

  • Motley Fool

    Can This Red-Hot Biotech Stock Keep Beating the Broader Markets?

    Acadia Pharmaceuticals (NASDAQ: ACAD), a commercial-stage biopharma specializing in treatments for central nervous disorders, is a potential market-beating play. Acadia Pharmaceuticals is a California-based pharma company with two Food and Drug Administration (FDA) approved medicines on the market. In 2016, the FDA approved the company's Parkinson's disease psychosis (PDP) medication Nuplazid, and in 2023, it green-lit its Rett Syndrome drug Daybue.